We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+15.52%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$482M
AUM Growth
+$99.4M
Cap. Flow
+$75.7M
Cap. Flow %
15.7%
Top 10 Hldgs %
61.57%
Holding
55
New
16
Increased
8
Reduced
12
Closed
12

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$35.2M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$14.4M
3
ARGX icon
argenx
ARGX
+$12.7M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$12M
5
BPMC
Blueprint Medicines
BPMC
+$11.1M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$19.1M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.1M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.7M
4
TVTX icon
Travere Therapeutics
TVTX
+$11.3M
5
ANAB icon
AnaptysBio
ANAB
+$8.4M

Sector Composition

Rank Sector Weight
1 Healthcare 72.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OBSV
51
DELISTED
ObsEva SA Ordinary Shares
OBSV
– –
-200,000
Closed -$2.56M
TCDA
52
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-150,000
Closed -$5.79M
BOLD
53
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-175,000
Closed -$6.83M
GNCA
54
DELISTED
Genocea Biosciences, Inc.
GNCA
– –
-250,000
Closed -$1.18M
BHVN
55
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-175,000
Closed -$9.01M
1 2
3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Ghost Tree Capital held 55 positions worth $482M, up 26% from $383M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Ghost Tree Capital deployed $75.7M of net new capital in Q2 2019, opening 16 new positions and adding to 8 existing holdings. Its largest new stake was Sarepta Therapeutics: 290,000 shares worth $44.1M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 84% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $19.1M trimmed.

  • Ghost Tree Capital's largest Q2 2019 buy was Sarepta Therapeutics: 290,000 shares worth $44.1M.
  • Ghost Tree Capital added most to Mirati Therapeutics, Inc. Common Stock in Q2 2019, an estimated $14.4M increase.
  • Ghost Tree Capital's biggest Q2 2019 reduction was Ascendis Pharma A/S, cutting an estimated $19.1M.
  • Ghost Tree Capital fully exited Vertex Pharmaceuticals in Q2 2019, selling an estimated $14.7M.
  • Ghost Tree Capital's ten largest holdings make up 62% of its $482M portfolio in Q2 2019.
  • Ghost Tree Capital opened 16 new positions and closed 12 in Q2 2019.
  • Ghost Tree Capital's portfolio value rose 26% quarter-over-quarter to $482M.

Based on Ghost Tree Capital's 13F filing for Q2 2019, filed 14 Aug 2019.